An engineered viral protein activates STAT5 to prevent T cell suppression
Authors:
- Yating ZhengYZYating Zheng
- Zehui GuZGZehui Gu
- Claire E. ShuddeCSClaire E. Shudde
- Taylor L. PiperTPTaylor L. Piper
- Grace A. AleckGAGrace A. Aleck
- Jiajia ZhouJZJiajia Zhou
- Dana KingDKDana King
- Monica K. ChandaMCMonica K. Chanda
- Lilliana TrinchLTLilliana Trinch
- Weiping ZouWZWeiping Zou
- Adam H. CourtneyACAdam H. Courtney
- 23 May 2025
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (107) , eadn9633
Abstract
T cell therapy efficacy can be compromised if cytokine-induced Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling is dysregulated or insufficient to sustain functionality. Here, we demonstrate that LCK kinase activity can be recruited to noncanonical protein substrates to directly activate targeted STAT proteins in T cells. STAT activation was accomplished by engineering the herpesvirus saimiri tyrosine kinase interacting protein (TIP) to provide a platform for the enforced recruitment of LCK to STAT proteins. We determined that a minimal region of TIP that binds to LCK could be combined with STAT binding sites derived from endogenous cytokine receptors. These constructs activated targeted STAT proteins in a cytokine-independent manner. We identified a STAT5 activator that sustained CD8+ T cell survival and cytotoxic function ex vivo in the absence of interleukin-2. Tumor outgrowth was reduced in vivo because of enhanced T cell persistence and functionality. Single-cell transcriptomics revealed that the STAT5 activator prevented the expression of genes associated with an exhausted T cell fate. Our findings demonstrate that signaling pathways can be rewired in T cells to sustain their function in solid tumors.Keywords
This publication has 85 references indexed in Scilit:
- A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseasesEBioMedicine, 2023
- The molecular details of cytokine signaling via the JAK/STAT pathwayProtein Science, 2018
- Structural Basis for the Recognition of c-Src by Its Inactivator CskCell, 2008
- T cell receptor antagonist peptides induce positive selectionCell, 1994
- ZAP-70: A 70 kd protein-tyrosine kinase that associates with the TCR ζ chainCell, 1992
- Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptorCell, 1992
- The human p50csk tyrosine kinase phosphorylates p56lck at Tyr‐505 and down regulates its catalytic activity.The EMBO Journal, 1992
- Interaction of the unique N-terminal region of tyrosine kinase p56lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifsCell, 1990
- Clinical effects and toxicity of interleukin-2 in patients with cancerCancer, 1986
- High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated CancerJAMA, 1986